Counteracting effect of papaverine on morphine inhibition of gastrointestinal transit in mice

Neurogastroenterology and Motility

Volumn 20, Issue 8, 2008, Pages 958-965

  Tucci, P ^a   Palmery, M ^b   Piccolotti, P ^b   Pimpinella, G ^c   Valeri, P ^b   Romanelli, L ^b  

^a UNIVERSITY OF FOGGIA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c ITALIAN MEDICINES AGENCY   (Italy)

Author keywords

Capsaicin; Intestinal motility; Morphine; Papaverine

Indexed keywords

CAPSAICIN; DEXAMETHASONE; INDOMETACIN; MORPHINE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; PAPAVERINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EXPOSURE; DRUG INHIBITION; DRUG MECHANISM; GASTROINTESTINAL TRANSIT; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SENSORY NERVE; UPPER GASTROINTESTINAL TRACT;

ANALGESICS, OPIOID; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CAPSAICIN; CONSTIPATION; DEXAMETHASONE; ENZYME INHIBITORS; GASTROINTESTINAL TRANSIT; GLUCOCORTICOIDS; HUMANS; INDOMETHACIN; MALE; MICE; MORPHINE; NG-NITROARGININE METHYL ESTER; PAPAVERINE; SENSORY SYSTEM AGENTS;

EID: 47649100779     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2008.01103.x     Document Type: Article

References (46)

1. Kromer W. Endogenous and exogenous opioids in the control of gastrointestinal motility and secretion. Pharmacol Rev 1988 40 : 121 62.
2. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 2001 182 (Suppl. 5A 11S 8S.
3. Walsh TD. Prevention of opioid side effects. J Pain Symptom Manage 1990 5 : 362 7.
4. Yuan CS, Foss JF, O'Connor M, Moss J, Roizen MF. Gut motility and transit changes in patients receiving long-term methadone maintenance. J Clin Pharmacol 1998 38 : 931 5.
5. Gutstein HB, Akil H. Opioid analgesics. In : Brunton LL, Lazo JS, Parker KL, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutic, 11th edn. New York : The McGraw-Hill Companies, 2006 : 569 619.
6. Clark AJ, Ahmedzai SH, Allan LG et al. Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain. Curr Med Res Opin 2004 20 : 1419 28.
7. Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs 2003 63 : 649 71.
8. Greenwood-Van Meerveld B, Gardner CJ, Little PJ, Hicks GA, Dehaven-Hudkins DL. Preclinical studies of opioids and opioid antagonists on gastrointestinal function. Neurogastroenterol Motil 2004 16 (Suppl. 2 46 53.
9. Kaneda T, Shimizu K, Nakajyo S, Urakawa N. The difference in the inhibitory mechanisms of papaverine on vascular and intestinal smooth muscles. Eur J Pharmacol 1998 355 : 149 57.
10. Schimizu K, Ichikawa T, Urakawa N, Nakajyo S. Inhibitory mechanism of papaverine on the smooth muscle of guinea pig urinary bladder. Jpn J Pharmacol 2000 83 : 143 9.
11. Jurna I, Jurna K, Baldauf J, Zenz M. Oral papaverine prevents morphine-induced constipation without interfering with analgesia achieved with oral morphine. Schmerz 1996 10 : 27 35.
12. Sawe J. High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment. Clin Pharmacokinet 1986 11 : 87 106.
13. Smith GD, Smith MT. The excitatory behavioral and antianalgesic pharmacology of normorphine-3-glucuronide after intracerebroventricular administration to rats. J Pharmacol Exp Ther 1998 285 : 1157 62.
14. Smith MT. Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3-glucuronide metabolites. Clin Exp Pharmacol Physiol 2000 27 : 524 8.
15. Smith GD, Smith MT. Morphine-3-glucuronide: evidence to support its putative role in the development of tolerance to the antinociceptive effects of morphine in the rat. Pain 1995 62 : 51 60.
16. Reid JJ, Beart PM, Marley PD. No problems down-under. Trends Pharmacol Sci 1996 7 : 205 8.
17. Szallasi A, Blumberg PM. Vanilloid (Capsaicin) receptors and mechanisms. Pharmacol Rev 1999 51 : 159 212.
18. Wilson DE, Kaymakcalan H. Prostaglandins: gastrointestinal effects and peptic ulcer disease. Med Clin North Am 1981 65 : 773 87.
19. Izzo AA, Capasso R, Pinto L, Di Carlo G, Mascolo N, Capasso F. Effect of vanilloid drugs on gastrointestinal transit in mice. Br J Pharmacol 2001 132 : 1411 6.
20. AVMA: American Veterinary Medical Association : 2000 report of the AVMA panel on euthanasia. JAVMA 2001 218 : 669 96.
21. Tan-No K, Niijima F, Nakagawasai O, Sato T, Satoh S, Tadano T. Development of tolerance to the inhibitory effect of loperamide on gastrointestinal transit in mice. Eur J Pharm Sci 2003 20 : 357 63.
22. Cadoni C, Di Chiara G. Reciprocal changes in dopamine responsiveness in the nucleus accumbens shell and core and in the dorsal caudate-putamen in rats sensitized to morphine. Neuroscience 1999 90 : 447 55.
23. Wells JL, Bartlett JL, Ananthan S, Bilsky EJ. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence. J Pharmacol Exp Ther 2001 297 : 597 605.
24. Smith DJ, Leil TA, Liu X. Neurotrophin-4 is required for tolerance to morphine in the mouse. Neurosci Lett 2003 340 : 103 6.
25. Matsuda H, Li Y, Yamahara J, Yoshikawa M. Inhibition of gastric emptying by triterpene saponin, momordin Ic, in mice: roles of blood glucose, capsaicin-sensitive sensory nerves, and central nervous system. J Pharmacol Exp Ther 1999 289 : 729 34.
26. Holzer P, Pabst MA, Lippe IT et al. Afferent nerve-mediated protection against deep mucosal damage in the rat stomach. Gastroenterology 1990 98 : 838 48.
27. Stefano GB, Cadet P, Fimiani C, Magazine HI. Morphine stimulates iNOS expression via a rebound from inhibition in human macrophages: nitric oxide involvement. Int J Immunopathol Pharmacol 2001 14 : 129 38.
28. Jiang X, Shi E, Nakajima Y, Sato S. COX-2 mediates morphine-induced delayed cardioprotection via an iNOS-dependent mechanism. Life Sci 2006 78 : 2543 9.
29. Lysle DT, How T. Heroin modulates the expression of inducible nitric oxide synthase. Immunopharmacology 2000 46 : 181 92.
30. Lanier RK, Ijames SG, Carrigan KA, Carelli RM, Lysle DT. Self-administration of heroin produces alterations in the expression of inducible nitric oxide synthase. Drug Alcohol Depend 2002 66 : 225 33.
31. Di Rosa M, Ialenti A, Ianaro A, Sautebin L. Interaction between nitric oxide and cyclooxygenase pathways. Prostaglandins Leukotrienes Essent Fatty Acids 1996 54 : 229 38.
32. Cuellar B, Fernandez AP, Lizasoain I et al. Up-regulation of neuronal NO synthase immunoreactivity in opiate dependence and withdrawal. Psychopharmacology 2000 148 : 66 73.
33. Heinzen EL, Pollack GM. The development of morphine antinociceptive tolerance in nitric oxide synthase-deficient mice. Biochem Pharmacol 2004 67 : 735 41.
34. Powell KJ, Hosokawa A, Bell A et al. Comparative effects of cyclo-oxygenase and nitric oxide synthase inhibition on the development and reversal of spinal opioid tolerance. Br J Pharmacol 1999 127 : 631 44.
35. Ozek M, Uresin Y, Gungor M. Comparison of the effects of specific and nonspecific inhibition of nitric oxide synthase on morphine analgesia, tolerance and dependence in mice. Life Sci 2003 72 : 1943 51.
36. Olsson C, Holmgren S. The control of gut motility. Comp Biochem Physiol A Mol Integr Physiol 2001 128 : 481 503.
37. Takahashi T. Pathophysiological significance of neuronal nitric oxide synthase in the gastrointestinal tract. J Gastroenterol 2003 38 : 421 30.
38. Izzo AA, Gaginella TS, Mascolo N, Capasso F. Recent findings on the mode of action of laxatives: the role of platelet activating factor and nitric oxide. Trends Pharmacol Sci 1998 19 : 403 5.
39. Rees DD, Palmer RMJ, Hodson HF, Moncada S. A specific inhibitor of nitric oxide formation from L-arginine attenuates endothelium-dependent relaxation. Br J Pharmacol 1989 96 : 418 23.
40. Gyires K. Neuropeptides and gastric mucosal homeostasis. Curr Top Med Chem 2004 4 : 63 73.
41. Szekely JI, Miglecz E, Bajusz S. Species differences in the relative analgesic potencies of some classical opiates and opioid peptides. Psychopharmacology 1984 82 : 400 2.
42. Oguri K, Hanioka N, Yoshimura H. Species differences in metabolism of codeine: urinary excretion of codeine glucuronide, morphine-3-glucuronide and morphine-6-glucuronide in mice, rats, guinea pigs and rabbits. Xenobiotica 1990 20 : 683 8.
43. Kenyon EM, Calabrese EJ. Extent and implications of interspecies differences in the intestinal hydrolysis of certain glucuronide conjugates. Xenobiotica 1993 23 : 373 81.
44. Williams CL, Bihm CC, Rosenfeld GC, Burks TF. Morphine tolerance and dependence in the rat intestine in vivo. J Pharm Exp Ther 1997 280 : 656 63.
45. Drexel H, Dzien A, Spiegel RW et al. Treatment of severe cancer pain by low-dose continuous subcutaneous morphine. Pain 1989 36 : 169 76.
46. Nelson KA, Glare PA, Declan W, Groh ES. A prospective, within-patient, crossover study of continuous intravenous and subcutaneous morphine for chronic cancer pain. J Pain Symptom Manage 1997 13 : 262 7.